NCT07130409 Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
| NCT ID | NCT07130409 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Affiliated Hospital of Qingdao University |
| Condition | Cardiac Magnetic Resonance Imaging |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-08 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-08 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \[PCI\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET/MR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET/MR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.
Eligibility Criteria
Inclusion Criteria: * Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure. Exclusion Criteria: * Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions. Patients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural/functional assessments. Prior history of myocardial infarction, coronary revascularization (PCI/CABG). Concurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic/autoimmune diseases, or severe hepatic/renal failure. Contraindications to CMR (claustrophobia, pacemaker implantation, etc.). Pregnant, breastfeeding, or women of childbearing potential without effective contraception. Sexually active individuals of reproductive age unwilling to use reliable contraception.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07130409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cardiac Magnetic Resonance Imaging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07130409 currently recruiting?
Yes, NCT07130409 is actively recruiting participants. Contact the research team at niepei@qdu.edu.cn for enrollment information.
Where is the NCT07130409 trial being conducted?
This trial is being conducted at Qingdao, China.
Who is sponsoring the NCT07130409 clinical trial?
NCT07130409 is sponsored by The Affiliated Hospital of Qingdao University. The trial plans to enroll 20 participants.